371 related articles for article (PubMed ID: 34740359)
1. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.
Ceriello A; Catrinoiu D; Chandramouli C; Cosentino F; Dombrowsky AC; Itzhak B; Lalic NM; Prattichizzo F; Schnell O; Seferović PM; Valensi P; Standl E;
Cardiovasc Diabetol; 2021 Nov; 20(1):218. PubMed ID: 34740359
[TBL] [Abstract][Full Text] [Related]
2. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
3. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.
Bertoni AG; Wagenknecht LE; Kitzman DW; Marcovina SM; Rushing JT; Espeland MA;
Obesity (Silver Spring); 2012 Jul; 20(7):1511-8. PubMed ID: 21959345
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
[TBL] [Abstract][Full Text] [Related]
5. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis.
Taylor CJ; Roalfe AK; Iles R; Hobbs FD
BMJ Open; 2014 Apr; 4(4):e004675. PubMed ID: 24747793
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
7. Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.
Dencker M; Stagmo M; Dorkhan M
Vasc Health Risk Manag; 2010 Jun; 6():373-82. PubMed ID: 20539839
[TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.
Ohkuma T; Jun M; Woodward M; Zoungas S; Cooper ME; Grobbee DE; Hamet P; Mancia G; Williams B; Welsh P; Sattar N; Shaw JE; Rahimi K; Chalmers J;
Diabetes Care; 2017 Sep; 40(9):1203-1209. PubMed ID: 28684396
[TBL] [Abstract][Full Text] [Related]
10. SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace.
Boffa U; McGrady M; Reid CM; Shiel L; Wolfe R; Liew D; Campbell DJ; Stewart S; Krum H
Aust Health Rev; 2017 May; 41(2):121-126. PubMed ID: 27096227
[TBL] [Abstract][Full Text] [Related]
11. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
12. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
13. Heart failure prevalence in the general population: SOBOTA-HF study rationale and design.
Lainscak M; Omersa D; Sedlar N; Anker SD; Farkas J
ESC Heart Fail; 2019 Oct; 6(5):1077-1084. PubMed ID: 31347289
[TBL] [Abstract][Full Text] [Related]
14. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.
Ibrahim N; Januzzi JL
Expert Rev Cardiovasc Ther; 2015; 13(9):1017-30. PubMed ID: 26198476
[TBL] [Abstract][Full Text] [Related]
15. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.
Jafri L; Kashif W; Tai J; Siddiqui I; Azam I; Shahzad H; Ghani F
BMC Nephrol; 2013 May; 14():117. PubMed ID: 23725445
[TBL] [Abstract][Full Text] [Related]
16. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.
Cantinotti M; Law Y; Vittorini S; Crocetti M; Marco M; Murzi B; Clerico A
Heart Fail Rev; 2014 Nov; 19(6):727-42. PubMed ID: 24473828
[TBL] [Abstract][Full Text] [Related]
17. N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort.
O'Donnell C; Ashland MD; Vasti EC; Lu Y; Chang AY; Wang P; Daniels LB; de Lemos JA; Morrow DA; Rodriguez F; O'Brien CG
J Am Heart Assoc; 2021 Dec; 10(24):e022913. PubMed ID: 34889112
[TBL] [Abstract][Full Text] [Related]
18. Relationship between CCR and NT-proBNP in Chinese HF patients, and their correlations with severity of HF.
Lu Z; Wang B; Wang Y; Qian X; Zheng W; Wei M
Biomed Res Int; 2014; 2014():106252. PubMed ID: 25250312
[TBL] [Abstract][Full Text] [Related]
19. Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium.
Vuori MA; Reinikainen J; Söderberg S; Bergdahl E; Jousilahti P; Tunstall-Pedoe H; Zeller T; Westermann D; Sans S; Linneberg A; Iacoviello L; Costanzo S; Salomaa V; Blankenberg S; Kuulasmaa K; Niiranen TJ
Cardiovasc Diabetol; 2021 Sep; 20(1):195. PubMed ID: 34583686
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M
Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
